Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC

Sponsor
Zhejiang University
Study ID
NCT02005120
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Intrapleural administration of bevacizumab
  • recombinant human endostatin — DRUG
    Intrapleural administration of recombinant human endostatin

Study Details

Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC). Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid. The other widely used treatment for MPE is recombinant human endostatin.

Key Dates

First listed
Dec 9, 2013
Start date
Dec 31, 2013
Status verified
Dec 2013
Primary completion
Dec 31, 2015
Completion
Dec 31, 2015

Study Design

Enrollment
20 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
    Bevacizumab
  • Experimental: Arm B
    recombinant human endostatin

Primary Outcome Measure

overall response rate (ORR) [ Time Frame: 12 months ]

Central Contacts

Related Studies